Search

Displaying results 3041 - 3050 of 8411 in total
  1. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  2. Drug

    Tromethamine

    go.drugbank.com/drugs/DB03754
    ApprovedInvestigational

    as an alkalizer. … An organic amine proton acceptor.

  3. Drug

    Tribromsalan

    go.drugbank.com/drugs/DB20138
    ApprovedWithdrawn

    Tribromsalan has a monoisotopic molecular weight of 446.81 Da.

  4. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season.

  5. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.

  6. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  7. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Mixtures: Regulex D CapInternational brands: Scatron D
  8. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  9. Drug

    Degarelix

    go.drugbank.com/drugs/DB06699
    ApprovedInvestigational

    Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

  10. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.